WallStSmart

InfuSystems Holdings Inc (INFU)vsStryker Corporation (SYK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Stryker Corporation generates 17645% more annual revenue ($25.27B vs $142.40M). SYK leads profitability with a 13.2% profit margin vs 5.5%. SYK appears more attractively valued with a PEG of 1.43. SYK earns a higher WallStSmart Score of 59/100 (C).

INFU

Buy

51

out of 100

Grade: C-

Growth: 6.0Profit: 5.0Value: 6.0Quality: 7.5
Piotroski: 6/9Altman Z: 1.96

SYK

Buy

59

out of 100

Grade: C

Growth: 6.0Profit: 6.5Value: 4.0Quality: 6.5
Piotroski: 3/9Altman Z: 2.18
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

INFUUndervalued (+26.5%)

Margin of Safety

+26.5%

Fair Value

$10.36

Current Price

$9.03

$1.33 discount

UndervaluedFair: $10.36Overvalued
SYKSignificantly Overvalued (-35.2%)

Margin of Safety

-35.2%

Fair Value

$223.02

Current Price

$305.66

$82.64 premium

UndervaluedFair: $223.02Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

INFU1 strengths · Avg: 10.0/10
EPS GrowthGrowth
123.9%10/10

Earnings expanding 123.9% YoY

SYK1 strengths · Avg: 9.0/10
Market CapQuality
$112.44B9/10

Large-cap with strong market position

Areas to Watch

INFU4 concerns · Avg: 3.5/10
PEG RatioValuation
1.734/10

Expensive relative to growth rate

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Market CapQuality
$186.48M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
5.5%3/10

5.5% margin — thin

SYK3 concerns · Avg: 3.7/10
P/E RatioValuation
33.9x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
2.6%4/10

2.6% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : INFU

The strongest argument for INFU centers on EPS Growth.

Bull Case : SYK

The strongest argument for SYK centers on Market Cap. PEG of 1.43 suggests the stock is reasonably priced for its growth.

Bear Case : INFU

The primary concerns for INFU are PEG Ratio, Altman Z-Score, Market Cap.

Bear Case : SYK

The primary concerns for SYK are P/E Ratio, Revenue Growth, Piotroski F-Score.

Key Dynamics to Monitor

INFU carries more volatility with a beta of 1.42 — expect wider price swings.

SYK is growing revenue faster at 2.6% — sustainability is the question.

SYK generates stronger free cash flow (415M), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

SYK scores higher overall (59/100 vs 51/100). INFU offers better value entry with a 26.5% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

InfuSystems Holdings Inc

HEALTHCARE · MEDICAL DEVICES · USA

InfuSystem Holdings, Inc., provides infusion pumps and related products and services in the United States and Canada. The company is headquartered in Rochester Hills, Michigan.

Stryker Corporation

HEALTHCARE · MEDICAL DEVICES · USA

Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.

Visit Website →

Want to dig deeper into these stocks?